Eko Low Ejection Fraction Tool (ELEFT) vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Eko Low Ejection Fraction Tool (ELEFT)

by Eko Health

ElucidVivo A.3

by Elucid

AI Verdict

Tool A, Eko Low Ejection Fraction Tool, is designed for early detection of low ejection fraction, a heart failure indicator, during routine physical exams using stethoscope data. In contrast, Tool B, ElucidVivo A.3, provides quantitative analysis of arterial plaque from CT angiography to aid in atherosclerosis patient stratification and treatment decisions. While both are cardiology AI tools, their distinct input modalities and specific clinical applications make them complementary rather than direct competitors.

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose Eko Low Ejection Fraction Tool (ELEFT) if your primary goal is to conduct rapid, non-invasive screening for early indicators of heart failure during routine physical examinations. This tool is ideal for clinicians in primary care or cardiology seeking to quickly identify patients at risk of low ejection fraction using an integrated digital stethoscope and AI analysis, providing immediate insights to prompt further diagnostic workup.

View Eko Low Ejection Fraction Tool (ELEFT) →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to refine atherosclerosis patient stratification and treatment planning. This tool is best suited for cardiologists, radiologists, and vascular surgeons who need detailed visualization and objective measurements of plaque characteristics, including lipid-rich necrotic core and calcifications, to optimize interventional or medical management decisions.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Eko Low Ejection Fraction Tool (ELEFT)	ElucidVivo A.3
Deployment	Unknown	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT offers broader usability by integrating with a common, non-invasive physical exam tool (stethoscope) and providing rapid results in approximately 15 seconds, making it accessible for routine screening in various clinical settings. ElucidVivo A.3, while powerful, requires specialized imaging (CT angiography) and interpretation, limiting its immediate usability to specific diagnostic workflows.

Clinical Value

ElucidVivo A.3

While ELEFT offers significant value in early heart failure screening, ElucidVivo A.3 provides a deeper, more precise diagnostic capability by quantifying arterial plaque composition and stability, validated against histology, and deriving fractional flow reserve (FFRct). This detailed analysis directly impacts patient stratification and optimizes treatment decisions for complex atherosclerosis.

Pricing & Value

Tie

Both tools require direct contact for pricing, making it impossible to compare their cost-effectiveness or overall value proposition without specific financial details. Both are positioned as enterprise solutions, and neither provides transparent pricing information publicly.

Enterprise Readiness

Eko Low Ejection Fraction Tool (ELEFT)

ELEFT explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. While ElucidVivo A.3's FDA clearance implies compliance, the explicit declarations from Eko Health provide greater transparency and assurance for enterprise readiness.

Innovation

ElucidVivo A.3

While ELEFT innovates by making cardiac screening more accessible through a routine physical exam, ElucidVivo A.3 demonstrates a deeper scientific and technological innovation. Its ability to objectively quantify specific plaque components and derive FFRct, validated against ground-truth histology, pushes the boundaries of non-invasive atherosclerosis assessment and offers more granular diagnostic insights.

Support & Docs

Eko Low Ejection Fraction Tool (ELEFT)

Eko Health provides a more transparent and robust support ecosystem, including a dedicated Help Center with extensive documentation, FAQs, and guides, along with various channels for customer assistance like email, scheduled phone calls, and a claims portal. Elucid Bioimaging's publicly available information on specific support and documentation is less comprehensive.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Eko Low Ejection Fraction Tool (ELEFT)	ElucidVivo A.3
Tool Name	Eko Low Ejection Fraction Tool (ELEFT)	ElucidVivo A.3
Company	Eko Health	Elucid Bioimaging
Primary Clinical Focus	Early detection of low ejection fraction (indicator of heart failure) during routine physical exams.	Quantitative analysis of arterial plaque composition and stability from CT angiography for atherosclerosis patient stratification and treatment optimization.
Input Data Type	ECG and heart sound recordings from Eko digital stethoscopes.	CT angiography images.
Key Analysis/Output	AI-powered low ejection fraction detection, results in approximately 15 seconds.	Quantitative analysis of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications; visualization of lesion-level plaque composition; 3D visualization of vessels; fractional flow reserve (FFRct) derivation.
Specialties	Cardiology, Family Medicine, Internal Medicine	Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring Eko Low Ejection Fraction Tool (ELEFT) and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do ELEFT and ElucidVivo A.3 integrate into existing clinical workflows for patient assessment and diagnosis?

ELEFT is designed for integration into routine physical exams, aiding in the early detection of low ejection fraction during a standard stethoscope examination, with results available in approximately 15 seconds. ElucidVivo A.3, on the other hand, integrates with PACS/EMR systems and is utilized for quantitative analysis of arterial plaque from CT angiography, fitting into radiology reading and cardiology review workflows for atherosclerosis patient stratification.

What is the typical depth of EHR integration for each tool, and how does it facilitate data flow and documentation?

ELEFT integrates with Eko digital stethoscopes and is part of the SENSORAu2122 platform, which can integrate with EMRs for seamless documentation. ElucidVivo A.3 is a software application that integrates with PACS/EMR, which is standard for medical imaging software, facilitating the transfer of imaging data and analysis results.

What are the key accuracy and sensitivity metrics for each tool in their respective clinical applications, and how are these validated?

ELEFT was clinically validated in a multi-site study of 3,456 patients, achieving an AUROC of 0.835 for detecting LVEF <40%, with 74.7% sensitivity and 77.5% specificity. ElucidVivo A.3 provides quantitative analysis of arterial plaque composition and stability, with its plaque characteristics validated against histology, which is considered the gold standard for plaque characterization.

Given their distinct applications, for which specific clinical scenarios or patient populations is each tool most appropriate?

ELEFT is most appropriate for primary care, family medicine, and internal medicine settings to aid in the early identification of heart failure risk during routine physical exams, particularly for patients at risk for heart failure. ElucidVivo A.3 is best suited for cardiology, radiology, and vascular surgery to stratify patients with atherosclerosis and optimize treatment decisions through detailed plaque analysis from CT angiography.

What is the expected learning curve for physicians and staff to effectively utilize each tool, and what is the typical time-to-value for clinical integration?

ELEFT integrates with familiar Eko digital stethoscopes and provides results in approximately 15 seconds, suggesting a relatively low learning curve and quick time-to-value for integrating early heart failure risk detection into routine exams. ElucidVivo A.3 involves advanced quantitative analysis of CT angiography images, which may require a more involved learning curve for detailed interpretation of plaque characteristics, though its objective quantification aims to provide actionable insights for treatment optimization.

What considerations should be made for multi-site rollout, and what level of ongoing support and training can be expected from each vendor?

Eko Health offers comprehensive onboarding, deployment assistance, and dedicated customer support, with scalability from single sites to large health systems for ELEFT and its SENSORAu2122 platform. For ElucidVivo A.3, while specific multi-site rollout support details are not provided, its nature as a medical image analysis system integrating with PACS/EMR suggests that standard enterprise-level support and training for imaging software would be expected.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Eko Low Ejection Fraction Tool (ELEFT) or ElucidVivo A.3

Backers

Who funded each tool's parent company.